The invention provides a fluorinated chitosan derivative as a drug carrier, which has the following structure: a fluorine-containing compound covalently attached to the backbone of chitosan. The chitosan has a molecular weight in the range of 1000-5000000, a degree of deacetylation of not less than 55%, and a viscosity in the range of 25-1000 cps. The fluorine-containing compound is a fluorine-containing aliphatic chain shown by the following chemical formula (I)

##STR00001##

or an aromatic ring with functional groups shown by the following formula (II)

##STR00002##

wherein R.sub.1 is halogen (fluorine, chlorine, bromine, iodine), or a halogen-substituted alkane, cycloalkane, aldehyde group, carboxyl group, alkenyl group, alkynyl group, hydroxyl group, sulfonyl chloride, sulfonic acid bond or mercapto group, for interacting with a primary amino group. The compounds of the present invention can be universally bound to a variety of drugs to promote drug absorption and bioavailability, and reduce toxicity.

Disclosed are compositions and methods for their use that can be used in cosmetic applications. The composition can include an effective amount of a Centella asiatica stem cells to reduce the activity of hyaluronidase in skin, an effective amount of tetradecyl aminobutyroylvalylamino butyric urea trifluoroacetate or Alpinia galanga leaf extract to promote the production of hyaluronic acid in skin, an effective amount of tripeptide-1 to promote the production of fibronectin and laminin in skin, and a dermatologically acceptable vehicle.

Disclosed are compositions and methods for their use that can be used in cosmetic applications. The composition can include an effective amount of a Centella asiatica stem cells to reduce the activity of hyaluronidase in skin, an effective amount of tetradecyl aminobutyroylvalylamino butyric urea trifluoroacetate or Alpinia galanga leaf extract to promote the production of hyaluronic acid in skin, an effective amount of tripeptide-1 to promote the production of fibronectin and laminin in skin, and a dermatologically acceptable vehicle.

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

The present invention relates to an oral plaque dispersion agent capable of effectively acting on dental plaque from the surface layer to the deep part thereof and exerting an excellent effect of dispersing the dental plaque. Specifically, the present invention relates to an oral plaque dispersion agent comprising (A) a water-soluble compound 3 or more of primary hydroxyl groups in the molecular structure and 100 or more and 200 or less of a chemical formula weight as an active component.

The present invention relates to an oral plaque dispersion agent capable of effectively acting on dental plaque from the surface layer to the deep part thereof and exerting an excellent effect of dispersing the dental plaque. Specifically, the present invention relates to an oral plaque dispersion agent comprising (A) a water-soluble compound 3 or more of primary hydroxyl groups in the molecular structure and 100 or more and 200 or less of a chemical formula weight as an active component.

Disclosed are oral care compositions having reduced tooth staining propensity and comprising in a pharmaceutically acceptable carrier, a cationic antimicrobial agent and an anti-stain agent comprising one or more materials from each of at least two of the following chemical groups: Group 1. anionic agents, Group 2. aldehydes, ketones, and other reactive carbonyl compounds and Group 3. nonionic ethoxylated surfactants.

Examples of cationic antimicrobial agent include quaternary ammonium compounds such as cetylpyridinium chloride, cetyl pyridinium fluoride, tetradecylpyridinium chloride, N-tetradecyl-4-ethyl pyridinium chloride and domiphen bromide; chlorhexidine; and metal ion sources to supply metal ions such as stannous, zinc or copper.

Disclosed are oral care compositions having reduced tooth staining propensity and comprising in a pharmaceutically acceptable carrier, a cationic antimicrobial agent and an anti-stain agent comprising one or more materials from each of at least two of the following chemical groups: Group 1. anionic agents, Group 2. aldehydes, ketones, and other reactive carbonyl compounds and Group 3. nonionic ethoxylated surfactants.

Examples of cationic antimicrobial agent include quaternary ammonium compounds such as cetylpyridinium chloride, cetyl pyridinium fluoride, tetradecylpyridinium chloride, N-tetradecyl-4-ethyl pyridinium chloride and domiphen bromide; chlorhexidine; and metal ion sources to supply metal ions such as stannous, zinc or copper.

The present description relates to an anti-aging composition comprising at least one plant extract. The composition can comprise at least two different anti-aging agents, wherein one the anti-aging agent is a plant extract. The combination of two anti-aging agents has a superior effect on regulating longevity compared to the use of one anti-aging agent. The plant extract is preferably selected from the group consisting of a Black cohosh extract, a Valerian extract, a Ginkgo biloba extract, a Celery seed extract, a White willow extract and a Passion flower extract.